Cadila Healthcare is currently trading at Rs. 385.90, up by 10.45 points or 2.78% from its previous closing of Rs. 375.45 on the BSE.
The scrip opened at Rs. 379.80 and has touched a high and low of Rs. 391.00 and Rs. 374.20 respectively. So far 100880 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 454.40 on 23-Oct-2015 and a 52 week low of Rs. 295.50 on 18-Jan-2016.
Last one week high and low of the scrip stood at Rs. 391.00 and Rs. 372.50 respectively. The current market cap of the company is Rs. 38528.55 crore.
The promoters holding in the company stood at 74.79%, while institutions and non-institutions held 16.87% and 8.33% respectively.
Cadila Healthcare’s Oral Solid Dosage drug manufacturing plant located at SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA following the inspection carried out in January 2016. The receipt of EIR indicates the successful closure of the inspection points (483s) raised. It may be mentioned that this plant is a separate manufacturing unit and does not form a part of the Moraiya formulations manufacturing facility.
Cadila Healthcare is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world.
